Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis

Abstract

Our findings support testing of MBZ as a possible low-toxicity therapy for medulloblastomas of various molecular subtypes, including tumors with acquired vismodegib resistance. Its antitumor mechanism may be partially explained by inhibition of tumor angiogenesis.